BeyondSpring (BYSI) Q2 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2024 earnings summary
13 Jun, 2025Executive summary
Report covers financial results for the six months ended June 30, 2024.
Net loss attributable to BeyondSpring Inc. narrowed to $7.3 million from $12.7 million year-over-year.
Financial highlights
Revenue increased to $1.0 million from $0.9 million compared to the same period last year.
Operating expenses decreased to $7.4 million from $13.5 million year-over-year.
Net loss per share improved to $(0.19) from $(0.33) year-over-year.
Cash and cash equivalents rose to $8.4 million as of June 30, 2024, up from $7.8 million at year-end 2023.
Total assets declined to $20.9 million from $24.8 million at December 31, 2023.
Key financial ratios and metrics
Gross margin not specified; revenue growth and expense reduction contributed to lower net loss.
Weighted-average shares outstanding increased slightly to 39.1 million from 39.0 million.
Latest events from BeyondSpring
- Plinabulin achieved Phase 3 survival benefit in NSCLC; financials strengthened and pipeline advanced.BYSI
Q4 202525 Mar 2026 - Biopharma firm registers 10M shares for R&D and corporate use, facing clinical and financial risks.BYSI
Registration Filing16 Dec 2025 - Up to 10M shares registered for flexible sale to fund R&D amid ongoing financial uncertainty.BYSI
Registration Filing16 Dec 2025 - Shareholders will vote on auditor ratification at the September 2025 annual meeting.BYSI
Proxy Filing2 Dec 2025 - Shareholders will vote to ratify CBIZ as auditor at the September 2025 AGM.BYSI
Proxy Filing2 Dec 2025 - Net loss narrowed, Plinabulin advanced in NSCLC, SEED divested and raised $30M, cash at $12.5M.BYSI
Q3 202512 Nov 2025 - Q2 2025 saw narrowed net loss, SEED divestiture progress, and clinical advances in oncology.BYSI
Q2 202513 Aug 2025 - Plinabulin and SEED's TPD platform deliver clinical and pipeline breakthroughs with strong pharma alliances.BYSI
Corporate Presentation4 Jul 2025 - Q1 2025 net income rose to $4.5M from SEED sale; Plinabulin advanced in cancer trials.BYSI
Q1 20256 Jun 2025